独家直击！蔚来李斌建言电池新时代：协力攻坚 共创未来

蔚来李斌建言电池新时代：协力攻坚 共创未来

重庆 - 在2024中国汽车重庆论坛上，蔚来创始人、董事长兼CEO李斌针对电池寿命问题发表了重要讲话，呼吁业界共同关注并解决这一电动汽车发展中的关键挑战。

李斌指出，目前电动汽车的电池寿命普遍无法与整车寿命相匹配，这将带来一系列问题，包括电池更换成本高、环境污染加剧以及消费者体验下降等。他强调，"车的寿命应该超过电池的寿命，这是一个比较大的问题⋯⋯呼吁大家提前关注这个事情，开发长寿命电池，为长期的电池质保，除了质保，以后的售后也要做规划。"

针对电池寿命难题，李斌提出了一系列切实可行的建议：

• 加大研发力度，攻克电池技术瓶颈：应鼓励企业和科研机构加大对电池材料、电池结构和电池管理系统的研发投入，不断提升电池能量密度、循环寿命和安全性水平。
• 建立健全电池回收利用体系：应加强电池回收利用体系建设，提高废旧电池的回收率和资源化利用率，降低电池生产对环境的影响。
• 倡导理性消费，延长电池使用寿命：应引导消费者养成良好的用车习惯，例如避免电池过充过放、定期进行电池保养等，延长电池使用寿命。

李斌还强调，在汽车产业加速内卷的背景下，"合作的重要性不容忽视"。他认为，单纯的价格竞争缺乏层次，应该更多地关注于提升产品和服务的价值。他呼吁行业能够注重产品的创新和价值提升，而非仅仅局限于价格战。

**业界人士普遍认为，李斌的呼吁具有重要现实意义。**电池寿命问题是制约电动汽车大规模推广应用的关键因素之一。只有协力攻坚，共创电池新时代，才能推动电动汽车产业的可持续发展。

附：

• 蔚来汽车于2016年成立，是一家致力于设计、制造和销售智能电动汽车的全球化新兴企业。
• 截至2024年6月，蔚来已在中国市场建立了超过1000座换电站，并计划在未来三年内将换电站数量扩展至10000座。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.